Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
5.40
-0.24 (-4.26%)
Feb 21, 2025, 4:00 PM EST - Market closed
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $3.42M in the quarter ending September 30, 2024, with 685.26% growth. This brings the company's revenue in the last twelve months to $4.42M, up 40.41% year-over-year. In the year 2023, Ensysce Biosciences had annual revenue of $2.23M, down -11.61%.
Revenue (ttm)
$4.42M
Revenue Growth
+40.41%
P/S Ratio
0.53
Revenue / Employee
$631,629
Employees
7
Market Cap
7.05M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
Dec 31, 2020 | 3.93M | 2.17M | 122.86% |
Dec 31, 2019 | 1.76M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ENSC News
- 18 days ago - Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment - Accesswire
- 4 weeks ago - Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR - Accesswire
- 6 weeks ago - Ensysce Biosciences Issues Annual Shareholder Letter - Accesswire
- 2 months ago - Ensysce Biosciences Regains Full Compliance with Nasdaq - Accesswire
- 2 months ago - Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product - Accesswire
- 2 months ago - Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR - Accesswire
- 2 months ago - Ensysce Biosciences Announces 1-for-15 Reverse Stock Split - Accesswire
- 3 months ago - Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial - Accesswire